KDventures (Q3 Update): Dilafor Dominates After Umecrine Write-Down - Redeye
Bildkälla: Stockfoto

KDventures (Q3 Update): Dilafor Dominates After Umecrine Write-Down - Redeye

KDventures' net asset value amounted to SEK647m (SEK677m) at the end of the third quarter, with the decline mainly driven by a SEK30m write-down of AnaCardio following its Series B. However, Umecrine Cognition's failed phase IIa study will cut reported NAV by SEK226m. Another setback was Modus paused enrolment in its phase IIa study. Dilafor now accounts for around 70% of our sum-of-the-parts. Management has started a broad review of the holdings and KDventures' own operations, which we think could lower costs and let Dilafor reach key milestones without dilution for shareholders. Our base case is SEK0.4 (SEK0.5).

KDventures' net asset value amounted to SEK647m (SEK677m) at the end of the third quarter, with the decline mainly driven by a SEK30m write-down of AnaCardio following its Series B. However, Umecrine Cognition's failed phase IIa study will cut reported NAV by SEK226m. Another setback was Modus paused enrolment in its phase IIa study. Dilafor now accounts for around 70% of our sum-of-the-parts. Management has started a broad review of the holdings and KDventures' own operations, which we think could lower costs and let Dilafor reach key milestones without dilution for shareholders. Our base case is SEK0.4 (SEK0.5).
Börsvärldens nyhetsbrev